Apnimed Inc. shares rose on Friday during the company's trading debut following an upsized initial public offering in the U.S. market.
The listing provides the late-stage drug developer with the necessary capital to advance its lead candidate, Oxnimbi. Because obstructive sleep apnea has historically relied on mechanical interventions, a successful oral medication could shift the standard of care for millions of patients.
Apnimed priced 12 million shares [1] at $16 each [1], raising approximately $192 million [2]. The company's stock price increased by 6.3% [2] on its first day of trading.
The proceeds from the offering are earmarked for the regulatory filing and launch plans for Oxnimbi, an oral treatment designed to manage obstructive sleep apnea. The company is currently awaiting a regulatory decision from the U.S. Food and Drug Administration, which is targeted for February 2027 [3].
Obstructive sleep apnea occurs when the airway becomes blocked during sleep, often requiring the use of continuous positive airway pressure machines. Apnimed is positioning Oxnimbi as a pharmacological alternative to these devices. The company intends to use the new capital to ensure the drug meets the necessary requirements for market entry, and to build the infrastructure needed for a commercial rollout.
The market's positive response to the IPO suggests investor confidence in the potential for a non-mechanical sleep apnea treatment. The company will now focus on the final stages of the regulatory process as it nears the 2027 target date [3].
“Apnimed priced 12 million shares at $16 each, raising approximately $192 million.”
The successful IPO of Apnimed underscores a growing investor appetite for pharmaceutical alternatives to mechanical medical devices. If Oxnimbi receives FDA approval in early 2027, it could disrupt the obstructive sleep apnea market by offering a systemic treatment option for patients who cannot tolerate or refuse the use of CPAP machines.
